REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under ticker TZAC, represents the post-combination entity formed through the merger of blank-check company Tenzing Acquisition Corp with clinical-stage pharmaceutical developer Reviva Pharmaceuticals. Tenzing Acquisition Corp completed its SPAC IPO in 2018, targeting the healthcare and life sciences sector. The combined company, which operates in the biopharmaceutical space with a focus on central nervous system and neuropsychiatric drug development, filed this 10-Q quarterly report with the SEC on January 10, 2020, reflecting its status as a reporting company following the closing of the business combination. For full filing data, financial metrics, and SPAC deal history on TZAC and hundreds of other transactions, sign up for complete access at SpacDesk.